Anti-androgen receptor
Showing 1 - 25 of >10,000
Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- ONC-392
- lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
- (no location specified)
Dec 27, 2022
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial
Not yet recruiting
- Locally Advanced Salivary Gland Carcinoma
- +3 more
- Biopsy
- +3 more
- (no location specified)
Jan 10, 2023
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma Trial in San Francisco (Apalutamide, Cetrelimab)
Recruiting
- Small Cell Neuroendocrine Carcinoma
- +2 more
- Apalutamide
- Cetrelimab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 21, 2022
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer Trial in
Recruiting
- Castration-Resistant Prostatic Cancer
- +4 more
- ARAT
- +2 more
-
Orange City, Florida
- +1 more
Nov 23, 2022
Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)
Recruiting
- Breast Cancer
- +2 more
-
Madison, WisconsinUniversity of Wisconsin School of Medicine and Public Health
Oct 18, 2022
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston
Recruiting
- Advanced Breast Carcinoma
- +17 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)
Not yet recruiting
- Urothelial Carcinoma Bladder
- Androgen Receptor Positive
- Degarelix
- Gemcitabine/Cisplatin
-
Providence, Rhode IslandLifespan Cancer Institute
May 1, 2023
Breast Cancer With or Without BRCA Mutation
Recruiting
- Breast Cancer
- Androgen receptor status and BRCA mutation
-
Varanasi, UP, IndiaBanaras Hindu University
Jun 2, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
Physical Function During ARSI Treatment
Recruiting
- Advanced Prostate Carcinoma
- androgen receptor signaling inhibitors
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Nov 8, 2022
Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)
Recruiting
- Salivary Gland Carcinoma
- Goserelin Acetate
- Pembrolizumab
-
Chicago, Illinois
- +6 more
Sep 22, 2022
Androgen Deprivation Therapy, Prostate Cancer, Hypertension Trial (Gonadotropin-Releasing Hormone Agonist, Androgen receptor
Not yet recruiting
- Androgen Deprivation Therapy
- +4 more
- Gonadotropin-Releasing Hormone Agonist
- +2 more
- (no location specified)
Jan 18, 2023
Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)
Not yet recruiting
- Triple-Negative Breast Cancer
- Trastuzumab Deruxtecan
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023
Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)
Active, not recruiting
- Androgen Receptor Positive
- +5 more
- Enobosarm
- +2 more
-
Corona, California
- +6 more
Jun 8, 2022
Androgen Receptor Polymorphism on Endometrial Cancer
Not yet recruiting
- Androgen Receptor Abnormal
- Endometrial Disorder
- Endometrial sampling and Peripheral blood collection
- FSFI Scale
- (no location specified)
Dec 12, 2021
Prostate Cancer, Malignant Tumor of Prostate, Secondary Malignant Tumor of Prostate Trial in Cleveland (drug, other, radiation)
Not yet recruiting
- Prostate Cancer
- +2 more
- Androgen deprivation therapy (ADT)
- +3 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center Seidman Cancer Cen
Nov 21, 2023
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [177Lu]Lu-PSMA-617
- +3 more
- (no location specified)
Jan 23, 2023
Prospective Androgen Receptor Signaling Inhibitors Resistance
Not yet recruiting
- Prostate Cancer
- +3 more
- (no location specified)
Nov 15, 2023